Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 4/20 | 0.73 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.73 |
| ▸ | SLK | Q9H2G2 | 3/20 | 0.73 |
| ▸ | EGFR | P00533 | 2/20 | 0.73 |
| ▸ | FRK | P42685 | 2/20 | 0.73 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.73 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 5/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.44 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.44 |
| ▸ | CIT | O14578 | 2/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.44 |
| ▸ | STK10 | O94804 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | RAF1 | P04049 | 2/20 | 0.44 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5444414 | 0.88 | MAP4K4 (0.67) | MAP4K4CSNK1DSLKEGFRFRK | |
| SCHEMBL14414458 | 0.85 | MAP4K4 (0.55) | MAP4K4CSNK1DSLKEGFRFRK | |
| SCHEMBL14414498 | 0.73 | MAP4K4 (0.52) | MAP4K4CSNK1DSLKEGFRFRK | |
| SCHEMBL14414311 | 0.73 | MAP4K4 (0.54) | MAP4K4CSNK1DSLKEGFRFRK | |
| SCHEMBL17088198 | 0.72 | BRAF (0.60) | MAP4K4CSNK1DSLKMAPK14MAPK11 | |
| SCHEMBL3913944 | 0.72 | MAP4K4 (0.53) | MAP4K4CSNK1DSLKEGFRFRK | |
| SCHEMBL14414169 | 0.72 | EGFR (0.51) | MAP4K4CSNK1DSLKEGFRFRK | |
| SCHEMBL14414437 | 0.72 | MAP4K4 (0.53) | MAP4K4CSNK1DSLKEGFRFRK | |
| SCHEMBL5096854 | 0.72 | MEN1 (0.42) | MAP4K4CSNK1DSLKEGFRFRK | |
| SCHEMBL3920313 | 0.71 | MAP4K4 (0.60) | MAP4K4CSNK1DSLKEGFRFRK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-7153959-B2 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | PHARMACIA CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| US-7071198-B1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1500657-A1 | Substituted pyrazoles as P38 kinase inhibitors | G.D. Searle LLC (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1144403-B1 | SUBSTITUTED PYRAZOLES AS P38 KINASE INHIBITORS | SEARLE LLC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040176433-A1 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | PHARMACIA CORPORATION | 2004-09-09 | — | — | US | disclosed |
| CN-1264377-A | Substituted pyrazoles as P38 kinase inhabitors | SEARLE & CO (US) | 2000-08-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176433-A1 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | MAPK1, IL1R1, TNF | MAP4K4 110/4885CSNK1D 254/4885SLK 3098/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | MAP4K4 40/4885CSNK1D 1168/4885SLK 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.